ENGOT-ov77 / DS6000-109 / REJOICE A Phase 2/3, Multicenter, Randomized Study of RaludotatugDeruxtecan(R-DXd), a CDH6-directed Antibody-drugConjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer